

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-31 (canceled).

Claim 32 (new): A polynucleotide encoding a variant single chain human tissue-type plasminogen activator protein having R275 and at least one other basic amino acid residue in the serine protease region substituted by a non-basic amino acid residue thereby disrupting the salt bridge interaction between aspartate 477 and lysine 429.

Claim 33 (new): An expression vector comprising the polynucleotide of claim 32.

Claim 34 (new): A cell comprising the expression vector of claim 33.

Claim 35 (new): A polynucleotide encoding a variant single chain human tissue-type plasminogen activator protein selected from the group consisting of R275E,H417D, R275E,H417E and R275E,K429Y.

Claim 36 (new): An expression vector comprising the polynucleotide of claim 35.

Claim 37 (new): A cell comprising the expression vector of claim 36.

Claim 38 (new): A diagnostic kit comprising antibodies to a variant single chain human tissue-type plasminogen activator protein having R275 and at least one other basic amino acid residue in the serine protease region substituted by a non-basic amino acid residue thereby disrupting the salt bridge interaction between aspartate 477 and lysine 429.

Claim 39 (new): A diagnostic kit comprising polynucleotides capable of hybridizing to the polynucleotide of claim 32.

Claim 40 (new): A method of making a variant single chain human tissue-type plasminogen activator protein comprising the step of culturing the cell of claim 37.

Claim 41 (new): The method of claim 40 further comprising the additional step of purifying the protein.